eSURFACE 1 and reSURFACE 2: Biological therapy improves psoriasis and CVD
As a fact, cardiovascular diseases (CVD) are highly prevalent in patients with psoriasis, and hence Professor Nehal Mehta and his team have been using this as a model to study inflammatory atherogenesis. In this MEDtalk, he presents very interesting results from the reSURFACE 1 and 2 regarding the association between psoriasis and CVD and how both conditions improve following biological therapy with tildrakizumab.
Få tilgang til artikkelen
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.